Targeting mTOR and survivin concurrently potentiates radiation therapy in renal cell carcinoma by suppressing DNA damage repair and amplifying mitotic catastropheHari K. Rachamala, Krishnendu Pal, Debabrata Mukhopadhyay et al.|Journal of Experimental & Clinical Cancer Research|2024Cited by 20
Targeting mTOR and Survivin Concurrently Potentiates Radiation Therapy in Renal Cell Carcinoma by Suppressing DNA Damage Repair and Amplifying Mitotic CatastropheHari K. Rachamala, Krishnendu Pal, Vijay Sagar Madamsetty et al.|Research Square|2023Cited by 4
Abstract B026: Combined inhibition of mammalian target of rapamycin (mTOR) and survivin augments radiation therapy in renal cell carcinomaKrishnendu Pal, Debabrata Mukhopadhyay, Enfeng Wang et al.|Cancer Research|2023Cited by 0